<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002950</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000065420</org_study_id>
    <secondary_id>YALE-HIC-9043</secondary_id>
    <secondary_id>NCI-G97-1158</secondary_id>
    <nct_id>NCT00002950</nct_id>
  </id_info>
  <brief_title>Topotecan Plus Sargramostim in Treating Patients With Advanced Cancer</brief_title>
  <official_title>Phase I/II Study of Topotecan (SKF 104864) With Recombinant GM-CSF (Sargramostim) Used as a Priming Agent in Advanced Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yale University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Yale University</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so&#xD;
      they stop growing or die. Colony-stimulating factors such as sargramostim may increase the&#xD;
      number of immune cells found in bone marrow or peripheral blood and may help a person's&#xD;
      immune system recover from the side effects of chemotherapy.&#xD;
&#xD;
      PURPOSE: Phase I/II trial to study the effectiveness of topotecan plus sargramostim in&#xD;
      treating patients who have advanced cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES: I. Identify a priming schedule of sargramostim (GM-CSF) that reduces the&#xD;
      percentage of progenitor cells in cycle at the time of chemotherapy administration in&#xD;
      patients with advanced malignancies. II. Determine the maximum tolerated dose and toxic&#xD;
      effects of topotecan when administered with sargramostim in these patients. III. Conduct a&#xD;
      preliminary assessment of the activity of this topotecan regimen in these patients.&#xD;
&#xD;
      OUTLINE: This is a dose escalation study of topotecan. Patients receive priming with&#xD;
      sargramostim (GM-CSF) on days -4 through -2. On day 0, topotecan IV is administered over 30&#xD;
      minutes. Cohorts of 6 patients receive escalating doses of topotecan. The maximum tolerated&#xD;
      dose (MTD) is defined as the dose preceding that at which 2 of 6 patients experience&#xD;
      dose-limiting toxicity (DLT). Sargramostim resumes on day 1 following topotecan, and&#xD;
      continues for 5 days or until sufficient hematologic recovery. The next course of topotecan&#xD;
      is given 48 hours later. Treatment repeats every 6 weeks for 4 courses. Patients are followed&#xD;
      every 3 months for the first year, then every 6 months thereafter.&#xD;
&#xD;
      PROJECTED ACCRUAL: 15-25 patients will be accrued for the duration of 18 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 26, 1996</start_date>
  <completion_date type="Actual">February 10, 2002</completion_date>
  <primary_completion_date type="Actual">February 10, 2002</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Unspecified Adult Solid Tumor, Protocol Specific</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>sargramostim</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>topotecan hydrochloride</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS: Histologically proven malignancy for which no alternative&#xD;
        treatment exists&#xD;
&#xD;
        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: ECOG 0-2 Life expectancy: At&#xD;
        least 3 months Hematopoietic: Platelet count at least 100,000/mm3 Absolute neutrophil count&#xD;
        at least 1500/mm3 Hepatic: Total bilirubin no greater than 2.0 mg/dL Renal: Creatinine&#xD;
        clearance at least 50 mL/min Other: No active infections HIV negative No other concurrent&#xD;
        medical condition&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: At least 3 weeks&#xD;
        since prior chemotherapy (6 weeks for nitrosoureas or mitomycin) Endocrine therapy: Not&#xD;
        specified Radiotherapy: No prior wide field radiotherapy No prior radiotherapy to greater&#xD;
        than 20% of bone marrow Surgery: Recovered from prior surgery&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas J. Rutherford, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Yale University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Yale Comprehensive Cancer Center</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06520-8028</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>March 25, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 26, 2004</study_first_posted>
  <last_update_submitted>August 13, 2020</last_update_submitted>
  <last_update_submitted_qc>August 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>unspecified adult solid tumor, protocol specific</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Topotecan</mesh_term>
    <mesh_term>Sargramostim</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

